The corporate venture arm of an international healthcare company is currently making equity investments out of a $200 million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

The firm is primarily interested in companies that are of strategic interest to its parent company. These include innovative companies developing Therapeutics, Diagnostics, Medical Technology and Healthcare IT. In the therapeutics space the firm is highly interest in Gene therapy and is also open to companies working with small molecules and biologics. In the Medical Device Space the firm is generally open to all technology types including, Fluid Management Systems, Infusion Systems/IV Tubing, Software enabled devices, Home Care, Hospital Hardware and Drug Delivery Devices. For indications the firm is interested in areas of Oncology, Hematology, Immunology, Inflammation, and Pulmonology, Renal, Regenerative Medicine and Orphan Diseases. The firm is stage agnostic and will consider companies from the pre-clinical phase to those that already have products on the market. The firm is not interested in companies working with laboratory tools or technology that aids in the research/discovery process in the life science space.

The firm is looking for privately held companies and while they prefer companies to have a complete management team in place they are also open to working with companies to fill in gaps in management. The firm will lead investments although they generally prefer to co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Eastern United States invests broadly in the life science sector, and considers investment opportunities globally. The firm is likely to make 4-6 allocations in the next 6 months. Allocations typically vary from $250,000 to $5 million, in the form of equity or convertible debt. Allocations are typically made at the venture stage of development, but may be made in seed rounds if a company already has proof of their product’s efficacy.

The firm invests broadly into therapeutic, medical device and healthcare IT sectors. The firm is not restricted by development phase or indication, but does require that there be evidence of a product’s efficacy prior to investment. Rather than focusing on specific technologies or indications, the firm is interested in opportunities that display a high level of innovation and a strong market possibility; this typically leads the fund not to invest in therapeutics for indications such as Alzheimer’s disease that have proven to be difficult to bring to market.

The firm seeks to invest in strong management teams that have considerable industry experience and an understanding of entrepreneurship. It is preferred that a company is developing a product that represents the first commercial opportunity in a particular area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private wealth group based in the Eastern United States invests on behalf of family offices and institutions, and makes direct investments in a variety of sectors including healthcare & life science. Investments in early-stage companies are typically in the form of equity, whereas debt investments in later-stage companies may be considered. The group’s allocations are highly variable but are generally over $1m, and are typically at least $3m. The firm primarily invests in US-based companies but Canada-based and other international companies may also be considered.

Within the life science sector the group has diverse interests, with a primary focus on medical devices at all stages of development and medical service providers (including biotech R&D services and healthcare IT companies). Investments in therapeutic drug development may also be considered but only at later stages (Phase II or later).

The group seeks to invest in solid management teams who are developing a product based on proprietary, patented technology which addresses a large market need. While the group may consider investments in pre-revenue companies, they require that a company have a defined path to revenues and will be profitable within three years.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A VC firm based in the United States is currently investing from its second fund, which had a first close of $36m in 2014 and is targeting a raise of $100m. The firm typically invests $2-5 million. The fimr invests primarily in the USA but is also open to considering opportunities in Canada.

The firm only invests in oncology companies. Within the oncology field, the firm invests in proprietary technologies in therapeutics, diagnostics and devices, and is open to investing in any form of cancer (including rare cancers), but has a preference for investing in large market opportunities. The firm prefers to invest in companies that have attained proof of concept animals and have entered clinical trials in humans

The firm prefer to work with highly qualified, experienced management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A VC fund with offices throughout the Unites States seeks to invest in early to late stage life science companies. The firm is investing out of its first fund of $125M which closed in late 2013. The firm can allocate up to $5M in equity per company. The firm prefers to invest in US-based companies but will consider truly exceptional opportunities around the world. The firm is actively seeking new investment opportunities. 

The firm is currently seeking to invest in biotech therapeutics, diagnostics, pharmaceuticals, and medical devices. For therapeutics, the firm looks for small molecules and biologics and is open to biosimilars and all indications including orphan indications. The firm will consider products in from preclinical to the late stages of clinical trials. For medical devices, the firm will invest as early as proof of concept. The firm is opportunistic in terms of subsectors and indications. 

The firm’s investment model differs from a traditional venture capital approach. The firm wants to back entrepreneurs who are already positioning themselves with potential acquirers. Most importantly, the firm is predicated on identifying exit opportunities and strategic corporate partners even before the investment is made. The firm requires a board seat in each portfolio company when they lead the investment. The firm seeks a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Family office based in the United States focuses on investments in the healthcare industry. The firm’s investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture growth capital to healthcare companies and typically invests in equity or convertible preferred equity after the series A round. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

The firm will consider investments in Medical Devices, Diagnostics and Healthcare IT sectors. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, patient monitoring, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management. The firm does not invest in companies developing small molecule or devices that need PMA. For medical device sector, the firm is most interested in class I and class II devices. The firm will not consider companies in pre-clinical stage, and typically invests in companies that are near or have reached commercialization.

The firm focuses on private companies with strong and experienced management team. The firm usually takes a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US based venture capital fund is looking to make seed and series A stage investments into life science companies with investments ranging anywhere from $500,000 initially to $25 million over the lifetime of the investment. The firm is actively reviewing opportunities throughout the United States and could make as many as 6 investments over the next year.

Within the life science space the firm is primarily focused on therapeutics. Within therapeutics the firm is opportunistic in terms of technology type and is open to both single asset and platform technology companies. The firm is most interest in companies targeting white space indications and is generally less interest in highly crowded areas including diabetes, Alzheimer’s and solid tumors. The firm is primarily interest in pre-clinical companies however they are open to later stage technologies as well pending it is a series A round or earlier.

The firm is looking for companies with experienced management teams and is very open to working with incomplete management teams. The firm looks to act as an active value adding investor and requires a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com